Aging-related changes in blood-brain barrier integrity and the effect of dietary fat

Neurodegenerative Diseases

Volumn 12, Issue 3, 2013, Pages 125-135

  Takechi, R ^a,b   Pallebage Gamarallage, M M ^a,b   Lam, V ^a,b   Giles, C ^a,b   Mamo, J C ^a,b  

^a CURTIN UNIVERSITY   (Australia)

^b Australian Technology Network   (Australia)

Author keywords

Aging; Blood brain barrier; Cholesterol; Neurodegenerative disorder; Neuroinflammation; Saturated fatty acid

Indexed keywords

CHOLESTEROL; FAT; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN G; PROTEIN S100B; SATURATED FATTY ACID; TIGHT JUNCTION PROTEIN; TRIACYLGLYCEROL;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CONTROLLED STUDY; DIETARY INTAKE; FAT INTAKE; FEMALE; INTERVENTION STUDY; LIPID BLOOD LEVEL; LOW FAT DIET; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84884281882     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000343211     Document Type: Article

References (44)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ: Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37: 13-25.
2. Zlokovic BV: The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
3. Vasilevko V, Passos GF, Quiring D, Head E, Kim RC, Fisher M, Cribbs DH: Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Ann NY Acad Sci 2010; 1207: 58-70.
4. Kalaria RN: Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev 2010; 68(suppl 2):S74-S87.
5. Dickstein DL, Walsh J, Brautigam H, Stockton SD Jr., Gandy S, Hof PR: Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med 2010; 77: 82-102.
6. Miyakawa T: Vascular pathology in Alzheimer's disease. Psychogeriatrics 2010; 10: 39-44.
7. Luchsinger JA, Mayeux R: Dietary factors and Alzheimer's disease. Lancet Neurol 2004; 3: 579-587.
8. Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Mamo JC: Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog Lipid Res 2010; 49: 159-170.
9. Takechi R, Galloway S, Pallebage-Gamarallage MM, Mamo JC: Chylomicron amyloid-beta in the aetiology of Alzheimer's disease. Atheroscler Suppl 2008; 9: 19-25.
10. Laitinen MH, Ngandu T, Rovio S, Helkala EL, Uusitalo U, Viitanen M, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M: Fat intake at midlife and risk of dementia and Alzheimer's disease: a population-based study. Dement Geriatr Cogn Disord 2006; 22: 99-107.
11. Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, Lutjohann D, Hartmann T, Tanila H: Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-Amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 2006; 23: 563-572.
12. Hooijmans CR, Van der Zee CE, Dederen PJ, Brouwer KM, Reijmer YD, van Groen T, Broersen LM, Lutjohann D, Heerschap A, Kiliaan AJ: DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 2009; 33: 482-498.
13. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA: Mediterranean diet and mild cognitive impairment. Arch Neurol 2009; 66: 216-225.
14. Cunnane SC, Plourde M, Pifferi F, Begin M, Feart C, Barberger-Gateau P: Fish, docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res 2009; 48: 239-256.
15. Takechi R, Galloway S, Pallebage-Gamarallage MM, Wellington CL, Johnsen RD, Dhaliwal SS, Mamo JC: Differential effects of dietary fatty acids on the cerebral distribution of plasma-derived apo B lipoproteins with amyloid-beta. Br J Nutr 2010; 103: 652-662.
16. Ghribi O, Golovko MY, Larsen B, Schrag M, Murphy EJ: Deposition of iron and beta-Amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J Neurochem 2006; 99: 438-449.
17. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA: Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000; 7: 321-331.
18. Shie FS, Jin LW, Cook DG, Leverenz JB, Le-Boeuf RC: Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 2002; 13: 455-459.
19. Alzheimer's Association: 2008 Alzheimer's disease facts and figures. Alzheimers Dement 2008; 4: 110-133.
20. Mooradian AD: Effect of aging on the bloodbrain barrier. Neurobiol Aging 1988; 9: 31-39.
21. Tripathy D, Yin X, Sanchez A, Luo J, Martinez J, Grammas P: Cerebrovascular expression of proteins related to inflammation, oxidative stress and neurotoxicity is altered with aging. J Neuroinflammation 2010; 7: 63.
22. Beard RS Jr., Reynolds JJ, Bearden SE: Hyperhomocysteinemia increases permeability of the blood-brain barrier by NMDA receptordependent regulation of adherens and tight junctions. Blood 2011; 118: 2007-14.
23. Elali A, Doeppner TR, Zechariah A, Hermann DM: Increased blood-brain barrier permeability and brain edema after focal cerebral ischemia induced by hyperlipidemia: role of lipid peroxidation and calpain-1/2, matrix metalloproteinase-2/9, and RhoA overactivation. Stroke 2011; 42: 3238-3244.
24. Takechi R, Galloway S, Pallebage-Gamarallage MM, Johnsen RD, Mamo JC: Threedimensional immunofluorescent double labelling using polyclonal antibodies derived from the same species: enterocytic colocalization of chylomicrons with Golgi apparatus. Histochem Cell Biol 2008; 129: 779-784.
25. Van Broeck B, Van Broeckhoven C, Kumar-Singh S: Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches. Neurodegener Dis 2007; 4: 349-365.
26. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, Duff K, Dickson D, Van Broeckhoven C: Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 2005; 167: 527-543.
27. Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, Mayberg MR, Kanner A, Ayumar B, Albensi B, Cavaglia M, Janigro D: Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci 2003; 21: 109-121.
28. Herrmann M, Ehrenreich H: Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor Neurol Neurosci 2003; 21: 177-190.
29. Steiner J, Bielau H, Bernstein HG, Bogerts B, Wunderlich MT: Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 2006; 77: 1284-1287.
30. Rothermundt M, Ohrmann P, Abel S, Siegmund A, Pedersen A, Ponath G, Suslow T, Peters M, Kaestner F, Heindel W, Arolt V, Pfleiderer B: Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 361-364.
31. Kleindienst A, Hesse F, Bullock MR, Buchfelder M: The neurotrophic protein S100B: value as a marker of brain damage and possible therapeutic implications. Prog Brain Res 2007; 161: 317-325.
32. Chaves ML, Camozzato AL, Ferreira ED, Piazenski I, Kochhann R, Dall'Igna O, Mazzini GS, Souza DO, Portela LV: Serum levels of S100B and NSE proteins in Alzheimer's disease patients. J Neuroinflammation 2010; 7: 6.
33. Bailer AJ: Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 1988; 16: 303-309.
34. Morgan NG: Fatty acids, beta-cell toxicity. Curr Opin Clin Nutr Metab Care 2009; 12: 117-122.
35. Patil S, Sheng L, Masserang A, Chan C: Palmitic acid-treated astrocytes induce BACE1 upregulation and accumulation of C-terminal fragment of APP in primary cortical neurons. Neurosci Lett 2006; 406: 55-59.
36. Diakogiannaki E, Morgan NG: Differential regulation of the ER stress response by longchain fatty acids in the pancreatic beta-cell. Biochem Soc Trans 2008; 36: 959-962.
37. Yao PM, Tabas I: Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway. J Biol Chem 2001; 276: 42468-42476.
38. Clare K, Hardwick SJ, Carpenter KL, Weeratunge N, Mitchinson MJ: Toxicity of oxysterols to human monocyte-macrophages. Atherosclerosis 1995; 118: 67-75.
39. Peng SK, Tham P, Taylor CB, Mikkelson B: Cytotoxicity of oxidation derivatives of cholesterol on cultured aortic smooth muscle cells and their effect on cholesterol biosynthesis. Am J Clin Nutr 1979; 32: 1033-1042.
40. Black JE, Polinsky M, Greenough WT: Progressive failure of cerebral angiogenesis supporting neural plasticity in aging rats. Neurobiol Aging 1989; 10: 353-358.
41. Rivard A, Fabre JE, Silver M, Chen D, Murohara T, Kearney M, Magner M, Asahara T, Isner JM: Age-dependent impairment of angiogenesis. Circulation 1999; 99: 111-120.
42. Chavez JC, LaManna JC: Hypoxia-inducible factor-1alpha accumulation in the rat brain in response to hypoxia and ischemia is attenuated during aging. Adv Exp Med Biol 2003; 510: 337-341.
43. Rapino C, Bianchi G, Di Giulio C, Centurione L, Cacchio M, Antonucci A, Cataldi A: HIF-1alpha cytoplasmic accumulation is associated with cell death in old rat cerebral cortex exposed to intermittent hypoxia. Aging Cell 2005; 4: 177-185.
44. Rivard A, Berthou-Soulie L, Principe N, Kearney M, Curry C, Branellec D, Semenza GL, Isner JM: Age-dependent defect in vascular endothelial growth factor expression is associated with reduced hypoxia-inducible factor 1 activity. J Biol Chem 2000; 275: 29643-29647.